BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Trametinib (GSK1120212) has received FDA approval as a monotherapy for the treatment of unresectable/metastatic BRAF-mutant malignant melanoma and for the treatment of anaplastic thyroid cancer in combination with dabrafenib (a BRAF inhibitor).